Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION: Phase 3 Study of SRP-9001 in Ambulatory and Non-Ambulatory Duchenne Muscular Dystrophy
2020-002372-13Phase 3Active
- Sponsor
- Sarepta Therapeutics
- Start
- Aug 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing SRP-9001 gene therapy with Placebo (2 arms). Primary endpoint: Change in PUL (V2.0) total score. Started Aug 2022; status: active.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2020-002372-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002372-13.